GCP
TARS icon

GSA Capital Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

GSA Capital Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$684K Buy
10,864
+6,843
+170% +$437K 0.04% 779
2026
Q1 		$282K Buy
4,021
+409
+11% +$28.6K 0.02% 1286
2025
Q4 		$296K Sell
3,612
-9,072
-72% -$677K 0.03% 1173
2025
Q3 		$754K Sell
12,684
-8,944
-41% -$440K 0.06% 580
2025
Q2 		$876K Buy
+21,628
New +$973K 0.06% 546
2024
Q4 		– Sell
-22,493
Closed -$740K – 2022
2024
Q3 		$740K Buy
+22,493
New +$632K 0.06% 655
2024
Q2 		– Sell
-5,738
Closed -$209K – 2018
2024
Q1 		$209K Sell
5,738
-13,228
-70% -$389K 0.02% 1396
2023
Q4 		$384K Buy
+18,966
New +$317K 0.03% 971

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GSA Capital Partners's TARS Position: Q2 2026 in Review

GSA Capital Partners increased its Tarsus Pharmaceuticals (TARS) stake by 170% in Q2 2026, buying an estimated $437K and bringing the position to 10,864 shares worth $684K. The position accounts for 0.04% of the portfolio, ranked #779.

GSA Capital Partners first reported a position in TARS in Q4 2023 and has held it in 8 quarters since. The position peaked at $876K in Q2 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • GSA Capital Partners held 10,864 shares of Tarsus Pharmaceuticals worth $684K as of Q2 2026.
  • GSA Capital Partners bought 6,843 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $437K.
  • Tarsus Pharmaceuticals made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #779 holding.
  • GSA Capital Partners first reported a position in Tarsus Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • GSA Capital Partners's Tarsus Pharmaceuticals position peaked at $876K in Q2 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.